Jon Napitupulu

Chapper Healthcare, now AscellaHealth’s global pharmaceutical wholesaler, distributor, and commercialization services arm, is marking its 50th anniversary with a...

Nilo Therapeutics has raised a $101 million Series A round and appointed industry veteran Kim Seth as CEO, signaling...

FDA has approved Regeneron’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as adjuvant therapy for adults with cutaneous squamous cell carcinoma (CSCC)...

InterCure reported first-half 2025 revenue of NIS 130 million, its eleventh straight period of positive adjusted EBITDA at 10%...

VIVUS has cut the retail cash price of Qsymia, its phentermine/topiramate extended‑release capsule for chronic weight management, to under...

Journey Medical will meet investors at two New York conferences in October: the 4th Annual ROTH Healthcare Opportunities Conference...

Nurexone Biologic reported new preclinical data for ExoPTEN, an exosome-delivered siRNA therapy targeting PTEN, showing a reproducible, dose-dependent restoration...

Nasus Pharma has signed comprehensive agreements with Aptar to support clinical development and planned commercialization of NS002, an intranasal...

Catalyst Pharmaceuticals will present a cluster of real-world evidence analyses across the October congresses, spanning the Child Neurology Society,...

60 Degrees Pharmaceuticals is launching B-FREE, a Phase 2 open-label trial evaluating the ARAKODA (tafenoquine) regimen as a potential...